上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

产品名称：Topovale　(Synonyms: ARC 111)

CAS 号：　500214-53-9

产品货号：S89238

生物活性：

Description

WM-3835 是一种有效的，高特异性 HBO1 (KAT7 or MYST2) 抑制剂，可直接与 HBO1 的乙酰辅酶 A 结合位点结合 WM-3835 激活细胞凋亡，同时抑制骨肉瘤 (OS) 细胞的增殖，迁移和侵袭。WM-3835 具有抗肿瘤活性，并有效抑制小鼠中骨肉瘤异种移植物的生长。

IC50 & Target[1]

Topoisomerase I

Cellular Effect

Cell Line	Type	Value	Description
HCT-116	GI_{50}	0.177 μM	Growth inhibition of human HCT-116 cells by Cell-titer96 assay
KB	IC_{50}	0.005 μM	Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1
KB 3-1	IC_{50}	0.005 μM	Concentration required to inhibit cell proliferation in KB3-1 tumor cell line
KB 3-1	IC_{50}	0.005 μM	Cytotoxicity against human KB3-1 cells by MTT method
KB 3-1	IC_{50}	0.005 μM	Cytotoxicity against human KB3-1 cells after 4 days by MTT assay
KB 3-1	IC_{50}	0.005 μM	Cytotoxicity against human KB3-1 cells after MTT assay
KB 3-1	IC_{50}	0.005 μM	Cytotoxicity against human KB3-1 cells after 4 days after MTT assay
KB 3-1	IC_{50}	0.005 μM	Cytotoxicity against human KB3-1 cells after 4 days by MTT method
KB 3-1	IC_{50}	0.005 μM	Inhibitory concentration against KB/V-1 cells overexpress MDR1
KB 3-1	IC_{50}	0.005 μM	Inhibitory concentration against KB3-1 cell line was determined
KB 3-1	IC_{50}	0.006 μM	Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP
KB-V1	IC_{50}	0.002 μM	Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method
KB-V1	IC_{50}	0.005 μM	Cytotoxicity against human KBV1 cells by MTT method
KB-V1	IC_{50}	0.005 μM	Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay
KB-V1	IC_{50}	0.005 μM	Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 after 4 days by MTT assay
KB-V1	IC_{50}	0.015 μM	Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay
P388	IC_{50}	0.001 nM	Cytotoxicity against human P388 cells
P388	IC_{50}	0.001 μM	Concentration required to inhibit cell proliferation in P388 tumor cell line
P388	IC_{50}	0.001 μM	Cytotoxicity against mouse P388 cells by MTT method

上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

	P388	IC_{50}	0.001 μM	Cytotoxicity against mouse P388 cells after 4 days by MTT assay
	P388	IC_{50}	0.001 μM	Cytotoxicity against mouse P388 cells after MTT assay
	P388	IC_{50}	0.001 μM	Cytotoxicity against mouse P388 cells after 4 days by MTT assay
	P388	IC_{50}	0.001 μM	Cytotoxicity against mouse P388 cells after 4 days by MTT method
	P388	IC_{50}	0.001 μM	Inhibitory concentration against P388 cell line in mouse leukemia was determine
	P388	IC_{50}	0.23 μM	Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
	P388	IC_{50}	0.23 μM	Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay
	P388	IC_{50}	0.23 μM	Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method
	P388	IC_{50}	0.23 μM	Inhibitory concentration against camptothecin-resistant variant of P388 cell line was determined
	P388CPT45	IC_{50}	0.23 μM	Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
	P388CPT45	IC_{50}	0.23 μM	Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
	RPMI 8402	IC_{50}	0.002 μM	Concentration required to inhibit cell proliferation in RPM18402 tumor cell line
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human RPMI8402 cells by MTT method
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human RPMI8402 cells after MTT assay
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human RPMI8402 cells after 4 days by MTT method
	RPMI 8402	IC_{50}	0.002 μM	Inhibitory concentration against lymphoblast RPMI 8402 cell line was determined
	RPMI 8402	IC_{50}	0.002 μM	Cytotoxicity against human lymphoblast tumor cell line RPM18402
	RPMI 8402	IC_{50}	0.9 μM	Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant
	RPMI	IC_{50}	0.9 μM	Cytotoxicity against camptothecin-resistant RPMI 8402

上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话：021-61312973　　传真：021-55068248
网址：www.shyuanye.com
邮箱：shyysw@sina.com

	8402			
	RPMI 8402	IC_{50}	0.9 μM	Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1

Solvent&Solubility

细胞实验:

DMSO 中的溶解度 : 4.03 mg/mL (9.56 mM; ultrasonic and adjust pH to 2 with TFA; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3728 mL	11.8638 mL	23.7276 mL
	5 mM	0.4746 mL	2.3728 mL	4.7455 mL
	10 mM	---	---	---

*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献

[1]. Li TK, et al. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res. 2003 Dec 1;63(23):8400-7.

完整储备液配制表：

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

储备液的保存方式和期限：-80° C, 6 months; -20° C, 1 month。-80° C 储存时，请在 6 个月内使用，-20° C 储存时，请在 1 个月内使用。

可选溶剂	质量 / 溶剂体积 / 浓度	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3728 mL	11.8638 mL	23.7276 mL	59.3190 mL
	5 mM	0.4746 mL	2.3728 mL	4.7455 mL	11.8638 mL